Oligogen, Inc. is a Japanese biotech startup founded in 2015 with a focus on developing stem cell therapies for central nervous system (CNS) diseases. The company's patented neural stem cell technology “OligoGenie” has garnered global recognition, with patents in over 29 countries. Oligogen, Inc. has made significant strides in its pre-clinical phase for several pipeline diseases. The startup recently secured a substantial ¥111.05M Venture Round investment on 10 August 2017, attracting notable investors such as Nissay Capital, SMBC Venture Capital, Sosei CVC, and Kyoto University Innovation Capital. Oligogen, Inc. demonstrates promise in the biotech and pharmaceutical industries, leveraging its innovative technologies to address critical unmet medical needs in the CNS therapeutic landscape.
No recent news or press coverage available for Oligogen, Inc..